Sindrome.del.Ovario.Poliquistico

Diagnóstico 97
Homeostasis model assessment: insulin
resistance and beta-cell function from
fasting plasma glucose and insulin concentrations
in man. Diabetologia. 1985;
28:412-9.
44
Kauffman RP, Baker VM, Dimarino P,
Gimpel T, Castracane VD. Polycystic
ovarian syndrome and insulin resistance
in white and Mexican American
women: a comparison of two distinct
populations. Am J Obstet Gynecol. 2002;
187:1362-9.
45
Marqués-Vidal P, Mazoyer E, Bongard
V, Gourdy P, Ruidavets JB, Drouet L,
et al. Prevalence of insulin resistance
syndrome in southwestern France and
its relationship with inflammatory and
hemostatic markers. Diabetes Care.
2002;25:1371-7.
46
Balen AH, Laven JS, Tan SL, Dewailly
D. Ultrasound assessment of the polycystic
ovary: international consensus
definitions. Hum Reprod Update. 2003;9:
505-14.
47
Swanson M, Sauerbrei EE, Cooperberg
PL. Medical implications of ultrasonically
detected polycystic ovaries. J Clin
Ultrasound. 1981;9:219-22.
48
Pache TD, Hop WC, Wladimiroff JW,
Schipper J, Fauser BC. How to discriminate
between normal and polycystic
ovaries. Radiol. 1992;17:589-93.
49
Jonard S, Robert Y, Cortet C, Decanter
C, Dewailly D. Ultrasound examination
of polycystic ovaries: is it worth counting
the follicles? Hum Reprod. 2003;18:
598-603.
50
Dewailly D, Ardaens Y, Robert Y. Evaluación
de los ovarios poliquísticos
mediante ultrasonografía. Cuad Med
Reprod. 1996;2:137-49.
51
Polson DW, Adams J, Wadsworth J,
Frank S. Polycystic ovaries: a common
finding in normal women. Lancet. 1988;
1:870-2.
52
Adams J, Polson DW, Franks S. Prevalence
of polycystic ovaries in women
with anovulation and idiopathic hirsutism.
BMJ. 1986;293:355-59.
53
Calaf J, Webb S. Regulación central de la
función gonadal. En: Vanrell J, Calaf J,
Balasch J, Viscasillas P, editores. Fertilidad
y Esterilidad Humanas. Barcelona:
Masson-Salvat Medicina; 1992. p. 11-23.
54
Bjoro T, Holmen J, Kruger O, Midthjell K,
Hunstad K, Schreiner T, et al. Prevalence
of thyroid disease, thyroid dysfunction
and thyroid peroxidase antibodies in a
large, unselected population. The Health
Study of Nord-Trondelag (HUNT). Eur J
Endocrinol. 2000;143:639-47.
55
Escobar-Morreale HF. Macroprolactinemia
in women presenting with hyperandrogenic
symptoms: Implications for
the management of polycystic ovary
syndrome. Fertil Steril. 2004;82:1697-9.
56
Corenblum B, Taylor PJ. The hyperprolactinemic
polycystic ovary syndrome
may not be a distinct entity. Fertil Steril.
1982;38:549-52.
57
Ashby CD. The laboratory evaluation of
hirsutism. AACC Endo. 1994;12:235-8.
58
Waggoner W, Boots LR, Azziz R. Total testosterone
and DHEAS levels as predictors
of androgen-secreting neoplasms: a
populational study. Gynecol Endocrinol.
1999;13:394-400.
59
New MI, Lorenze F, Lerner AJ, et al.
Genotyping steroid 21-hydrosilase deficiency:
hormonal reference data. J Clin
Endocrinol Metab. 1983;57:320-6.
60
Azziz R, Hincapie LA, Knochenhauer ES,
Dewailly D, Fox L, Boots LR. Screening
for 21-hydroxylase deficient non-classic
adrenal hyperplasia among hyperandrogenic
women: a prospective study. Fertil
Steril. 1999;72:915-25.
61
Rodríguez-Espinosa J, Calaf J. Estrategia
para el escrutinio de formas no
clásicas de hiperplasia suprarrenal congénita
por deficiencia de P450c21 en
mujeres hiperandrogénicas. Med Clin.
1994;103:645-51.
62
Ibáñez L, Potau N, Zampolli M, Prat
N, Gussinyé M, et al. Source localization
of androgen excess in adolescent
girls. J Clin Endocrinol Metab. 1994;79:
1778-84.